Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment

Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively unselective immunosuppressive properties. However, two target-specific biological drugs have been approved: belimumab (anti-B-cell-activating factor/BAFF) and anifrolumab (anti-interferon alpha receptor-1/IFNAR1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirou, Kyriakos A., Dall`Era, Maria, Aranow, Cynthia, Anders, Hans-Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472122/
https://www.ncbi.nlm.nih.gov/pubmed/36119023
http://dx.doi.org/10.3389/fimmu.2022.980079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472122/
https://www.ncbi.nlm.nih.gov/pubmed/36119023
http://dx.doi.org/10.3389/fimmu.2022.980079

Ejemplares similares